Trinity Biotech Announces Quarter 4 Results

Profit Before Tax Increases by 16% Excluding the Impact of Restructuring Expenses and Impairment

DUBLIN, IRELAND - Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter and year ended December 31, 2008.

Quarter 4 2008 Results

Revenues for quarter 4, 2008 amounted to US$34.0m compared to US$35.7m for quarter 4, 2007, a decrease of 4.8%. This included a decrease 5.1% in our Point of Care revenues and 4.7% in our Clinical Laboratory revenues. Compared to revenues of US$35.6m in quarter 3, 2008, revenues in quarter 4 have also fallen by approximately 4.4%. However, this fall is entirely attributable to currency movements.

Read More

Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News